GlassScriptPhysician profile
Stephen J Pigman
NPI 1255750725
$1,284.78
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $517 · 2023: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $488.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.29 | 2022-2023 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $76.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.76 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $75.28 | 2021-2023 | Farxiga |
| Sumitomo Pharma America, INC. | $71.22 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $60.21 | 2021-2023 | Xarelto |
| Clarus Therapeutics INC. | $58.51 | 2021 | |
| Antares Pharma, INC. | $57.50 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Corium, LLC | $54.66 | 2023 | Azstarys |
| Glaxosmithkline, LLC. | $51.90 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.48 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $45.69 | 2022 | |
| Abbott Laboratories | $41.78 | 2023 | Freestyle Libre 3 |
| Abbvie INC. | $41.64 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.31 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $35.09 | 2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $27.93 | 2022 | |
| Shield Therapeutics INC | $27.18 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $25.94 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.01 | 2022 | |
| Halozyme INC | $18.67 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.78 | 2022 | |
| Amarin Pharma, INC. | $16.63 | 2022 | |
| Medtronic, INC. | $16.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.88 | 2022 | |
| Pfizer INC. | $15.74 | 2021 | |
| Mylan Specialty L.P. | $15.72 | 2021 | |
| Axonics, INC. | $13.74 | 2022 | |
| Novo Nordisk INC | $12.89 | 2022 | |
| Eisai INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pigman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.